Hosted on MSN

Bivalent CAR-T Cells Via CSF Injection Show Activity in Recurrent Glioblastoma

CHICAGO -- Intracerebroventricular (ICV) delivery of bivalent CAR T-cells targeting EGFR and IL13Rα2 was feasible and appeared safe in patients with recurrent glioblastoma (GBM) in a phase I study ...
Seeking Alpha

Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference

CNSide® may catalyze LM treatment initiation, allow physicians to adapt treatment with real time shifts in tumor biology, and enable personalized cancer therapy HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) ...
ascopubs.org

Clinical Utility of a Circulating Tumor Cell–Based Cerebrospinal Fluid Assay in the Diagnosis and Molecular Analysis of Leptomeningeal Disease in Patients With Advanced Non ...

Patients with NSCLC who had CSF collection as part of routine clinical care for suspected LMD were included in the study. CSF was evaluated for CTCs and cfDNA using a commercial assay (CNSide; Biocept ...
Nasdaq

Plus Therapeutics' CNSide Showcases Innovative CSF Assay Data at SNO/ASCO CNS Metastases Conference 2025

Plus Therapeutics, Inc. announced that its subsidiary, CNSide Diagnostics, will present data at the SNO/ASCO CNS Metastases Conference from August 14-16, 2025, in Baltimore, MD. The presentations will ...
GEN

Migraines Triggered by CSF Flow between Brain and Peripheral Nervous System

Research headed by teams at the University of Rochester Center for Translational Medicine and the University of Copenhagen describes for the first time how a spreading wave of disruption and the flow ...
Business Insider

Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases

CNSide Cerebrospinal Fluid (CSF) Assay analyzed 258 CSF samples across 66 leptomeningeal metastases (LM) patients at five institutions CNSide identified extensive, actionable mutational changes, and ...